Edition:
United Kingdom

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

35.92USD
15 Dec 2017
Change (% chg)

$-0.08 (-0.22%)
Prev Close
$36.00
Open
$36.10
Day's High
$36.10
Day's Low
$35.40
Volume
691,167
Avg. Vol
141,420
52-wk High
$40.35
52-wk Low
$23.07

Chart for

About

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $1,680.20
Shares Outstanding(Mil.): 44.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions

14 Nov 2017

BRIEF-Acceleron Pharma qtrly net loss per share $0.65

* Acceleron Pharma reports third quarter 2017 operational and financial results

07 Nov 2017

BRIEF-Acceleron announces pricing of public offering of common stock

* Acceleron announces pricing of public offering of common stock

21 Sep 2017

BRIEF-Acceleron announces proposed public offering of common stock

* Acceleron announces proposed public offering of common stock

19 Sep 2017

BRIEF-Acceleron Pharma Q2 loss per share $0.77

* Acceleron Pharma reports second quarter 2017 operational and financial results

03 Aug 2017

BRIEF-Acceleron announces first patient treated in phase 2 clinical trial of ACE-083

* Acceleron announces first patient treated in phase 2 clinical trial of ACE-083 in Charcot-Marie-Tooth disease Source text for Eikon: Further company coverage:

01 Aug 2017

Earnings vs. Estimates